Modeling the Pharmacogenetic Architecture of Drug Response

Yafei Lu, Xin Li, Sisi Feng, Yongci Li, Xiaofeng Zeng, Mengtao Li, Xinjuan Liu, Rongling Wu

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Clinical pharmacogenomics, aimed at integrating genomic information with clinical practices to facilitate the prediction of drug response, has recently emerged as a vital area of public health. To make clinical pharmacogenomics a success, we need a comprehensive understanding of how genes singly or interactively affect patients' response to a particular drug. In this chapter, we review statistical designs for mapping the genetic architecture of drug response using molecular markers. Genes that affect a pharmacological response, their number, genomic distribution, and genetic actions and interactions can be estimated and tested. Functional mapping that integrates genetic mapping with pharmacodynamic and pharmacokinetic machineries of drug response can improve the precision of mapping results and their clinical interpretations. Genome-wide association studies (GWASes), beyond traditional genetic mapping approaches, provide an unprecedented opportunity to chart a complete picture of the genetic control of drug response. The implementation of GWASes by functional mapping leads to the birth of a dynamic model, fGWAS, for studying and characterizing clinical pharmacogenomics toward personalized medicine. © 2013

Original languageEnglish (US)
Title of host publicationPharmacogenomics
PublisherElsevier Inc.
Pages295-308
Number of pages14
ISBN (Print)9780123919182
DOIs
StatePublished - Aug 27 2013

Fingerprint

Pharmacogenetics
Genome-Wide Association Study
Pharmaceutical Preparations
Precision Medicine
Drug and Narcotic Control
Genes
Pharmacokinetics
Public Health
Parturition
Pharmacology

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology

Cite this

Lu, Y., Li, X., Feng, S., Li, Y., Zeng, X., Li, M., ... Wu, R. (2013). Modeling the Pharmacogenetic Architecture of Drug Response. In Pharmacogenomics (pp. 295-308). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-391918-2.00017-2
Lu, Yafei ; Li, Xin ; Feng, Sisi ; Li, Yongci ; Zeng, Xiaofeng ; Li, Mengtao ; Liu, Xinjuan ; Wu, Rongling. / Modeling the Pharmacogenetic Architecture of Drug Response. Pharmacogenomics. Elsevier Inc., 2013. pp. 295-308
@inbook{06f9b5322f8d4f6c9f836490487176cd,
title = "Modeling the Pharmacogenetic Architecture of Drug Response",
abstract = "Clinical pharmacogenomics, aimed at integrating genomic information with clinical practices to facilitate the prediction of drug response, has recently emerged as a vital area of public health. To make clinical pharmacogenomics a success, we need a comprehensive understanding of how genes singly or interactively affect patients' response to a particular drug. In this chapter, we review statistical designs for mapping the genetic architecture of drug response using molecular markers. Genes that affect a pharmacological response, their number, genomic distribution, and genetic actions and interactions can be estimated and tested. Functional mapping that integrates genetic mapping with pharmacodynamic and pharmacokinetic machineries of drug response can improve the precision of mapping results and their clinical interpretations. Genome-wide association studies (GWASes), beyond traditional genetic mapping approaches, provide an unprecedented opportunity to chart a complete picture of the genetic control of drug response. The implementation of GWASes by functional mapping leads to the birth of a dynamic model, fGWAS, for studying and characterizing clinical pharmacogenomics toward personalized medicine. {\circledC} 2013",
author = "Yafei Lu and Xin Li and Sisi Feng and Yongci Li and Xiaofeng Zeng and Mengtao Li and Xinjuan Liu and Rongling Wu",
year = "2013",
month = "8",
day = "27",
doi = "10.1016/B978-0-12-391918-2.00017-2",
language = "English (US)",
isbn = "9780123919182",
pages = "295--308",
booktitle = "Pharmacogenomics",
publisher = "Elsevier Inc.",
address = "United States",

}

Lu, Y, Li, X, Feng, S, Li, Y, Zeng, X, Li, M, Liu, X & Wu, R 2013, Modeling the Pharmacogenetic Architecture of Drug Response. in Pharmacogenomics. Elsevier Inc., pp. 295-308. https://doi.org/10.1016/B978-0-12-391918-2.00017-2

Modeling the Pharmacogenetic Architecture of Drug Response. / Lu, Yafei; Li, Xin; Feng, Sisi; Li, Yongci; Zeng, Xiaofeng; Li, Mengtao; Liu, Xinjuan; Wu, Rongling.

Pharmacogenomics. Elsevier Inc., 2013. p. 295-308.

Research output: Chapter in Book/Report/Conference proceedingChapter

TY - CHAP

T1 - Modeling the Pharmacogenetic Architecture of Drug Response

AU - Lu, Yafei

AU - Li, Xin

AU - Feng, Sisi

AU - Li, Yongci

AU - Zeng, Xiaofeng

AU - Li, Mengtao

AU - Liu, Xinjuan

AU - Wu, Rongling

PY - 2013/8/27

Y1 - 2013/8/27

N2 - Clinical pharmacogenomics, aimed at integrating genomic information with clinical practices to facilitate the prediction of drug response, has recently emerged as a vital area of public health. To make clinical pharmacogenomics a success, we need a comprehensive understanding of how genes singly or interactively affect patients' response to a particular drug. In this chapter, we review statistical designs for mapping the genetic architecture of drug response using molecular markers. Genes that affect a pharmacological response, their number, genomic distribution, and genetic actions and interactions can be estimated and tested. Functional mapping that integrates genetic mapping with pharmacodynamic and pharmacokinetic machineries of drug response can improve the precision of mapping results and their clinical interpretations. Genome-wide association studies (GWASes), beyond traditional genetic mapping approaches, provide an unprecedented opportunity to chart a complete picture of the genetic control of drug response. The implementation of GWASes by functional mapping leads to the birth of a dynamic model, fGWAS, for studying and characterizing clinical pharmacogenomics toward personalized medicine. © 2013

AB - Clinical pharmacogenomics, aimed at integrating genomic information with clinical practices to facilitate the prediction of drug response, has recently emerged as a vital area of public health. To make clinical pharmacogenomics a success, we need a comprehensive understanding of how genes singly or interactively affect patients' response to a particular drug. In this chapter, we review statistical designs for mapping the genetic architecture of drug response using molecular markers. Genes that affect a pharmacological response, their number, genomic distribution, and genetic actions and interactions can be estimated and tested. Functional mapping that integrates genetic mapping with pharmacodynamic and pharmacokinetic machineries of drug response can improve the precision of mapping results and their clinical interpretations. Genome-wide association studies (GWASes), beyond traditional genetic mapping approaches, provide an unprecedented opportunity to chart a complete picture of the genetic control of drug response. The implementation of GWASes by functional mapping leads to the birth of a dynamic model, fGWAS, for studying and characterizing clinical pharmacogenomics toward personalized medicine. © 2013

UR - http://www.scopus.com/inward/record.url?scp=84882839834&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882839834&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-391918-2.00017-2

DO - 10.1016/B978-0-12-391918-2.00017-2

M3 - Chapter

AN - SCOPUS:84882839834

SN - 9780123919182

SP - 295

EP - 308

BT - Pharmacogenomics

PB - Elsevier Inc.

ER -

Lu Y, Li X, Feng S, Li Y, Zeng X, Li M et al. Modeling the Pharmacogenetic Architecture of Drug Response. In Pharmacogenomics. Elsevier Inc. 2013. p. 295-308 https://doi.org/10.1016/B978-0-12-391918-2.00017-2